Antimicrobials
Imipenem-Cilastatin

Imipenem-Cilastatin

Restricted

Medium
N/A

Dosing

General Information

  • Bloodstream infections
  • Diabetic Foot infection
  • Neutropenic fever
  • Pneumonia 
  • Sepsis
  • Hypersensitivity to imipenem/cilastatin or any component of the formulation
  • Stenotrophomonas, MRSA, Enterococcus faecium, or VRE
  • Atypical infections like Legionella

Periodic renal, hepatic, and hematologic function tests.

  • Decreased hematocrit and hemoglobin
  • Thrombocythemia
  • Increased serum AST and ALT
  • FDA labeled indications
  • Blood stream infection, gram-ve bacteremia
  • Complicated intraabdominal infections, healthcare associated or high risk community acquired
  • Diabetic foot infection
  • Skin and soft tissue infection
  • Complicated urinary tractinfection
  • Ganciclovir-Valganciclovir: Generalized seizures have been observed with concurrent use of imipenem/cilastatin and ganciclovir.
  • Valproate Products: Concurrent use of carbapenem antibiotics with valproate products is generally not recommended. 
  • CycloSPORINE: Monitor for signs and symptoms of neurotoxicity. In addition, monitor for altered serum concentrations and associated toxicities of cyclosporine if used concomitantly with imipenem.

Antimicrobial class: Imipenem Inhibits bacterial cell wall synthesis. Cilastatin prevents renal metabolism of imipenem by competitive inhibition of dehydropeptidase along the brush border of the renal tubules

Elimination half-life: 60 min

Lung penetration: Therapeutic

Pancreatic tissue penetration: Therapeutic

Bone penetration: Poor

Pregnancy category: Category C

Breastfeeding: Acceptable

Adapted from the Nova Scotia Health Antimicrobial Stewardship Program